Zoetis Inc. $ZTS Holdings Decreased by Zurich Insurance Group Ltd FI

Key Points

• Zurich Insurance Group Ltd FI significantly reduced its stake in Zoetis Inc. by 88.3%, selling 97,432 shares and holding only 12,900 shares at the end of the first quarter.
• In a recent earnings report, Zoetis surpassed expectations with an EPS of $1.76 and revenue of $2.46 billion, marking a 4.2% year-over-year increase.
• Analyst ratings for Zoetis are mixed, with five analysts issuing a Buy rating and a consensus price target around $200.88.

Zurich Insurance Group Ltd FI decreased its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 88.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,900 shares of the company's stock after selling 97,432 shares during the period. Zurich Insurance Group Ltd FI's holdings in Zoetis were worth $2,124,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. 1248 Management LLC bought a new stake in shares of Zoetis in the 1st quarter worth approximately $27,000. Saudi Central Bank bought a new stake in shares of Zoetis in the 1st quarter worth approximately $29,000. Cornerstone Planning Group LLC raised its stake in Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after acquiring an additional 88 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its stake in Zoetis by 87.6% during the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock valued at $42,000 after acquiring an additional 120 shares in the last quarter. Finally, Sound Income Strategies LLC raised its stake in Zoetis by 141.4% during the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after acquiring an additional 164 shares in the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Price Performance

Shares of NYSE ZTS traded down $2.28 during mid-day trading on Friday, reaching $148.33. The company had a trading volume of 3,111,229 shares, compared to its average volume of 2,278,915. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The stock has a market cap of $65.74 billion, a PE ratio of 25.53, a P/E/G ratio of 2.42 and a beta of 0.89. The company has a 50-day moving average price of $152.32 and a two-hundred day moving average price of $157.31.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter in the previous year, the company posted $1.56 earnings per share. Zoetis's revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ZTS. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Argus reiterated a "buy" rating and set a $190.00 price target on shares of Zoetis in a research report on Tuesday. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and lowered their price target for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Piper Sandler lifted their price target on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. Finally, Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.